Jun 21, 2012 - 2006;80:486e501. 18. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, .... Sep 14;56(12):919e933. 48. Price MJ, Berger PB, ... Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and. CYP2C19: ethnic ...
Key words. Rheumatoid arthritis, methotrexate, ABCB1, polymorphism, drug sensitivity. Clinical and Experimental Rheumatology 2006; 24: 546-554.
Jun 5, 2015 - George MM, Copeland KC. Current treatment options for type 2 diabetes mellitus in youth: today's realities and lessons from the. Today study.
Benjie Wang, PhD, Lei Yang, PhD, Qingyu Meng, PhD. Abstract. Background and ... changes caused by osteocyte death under the effects of complicated factors ...
European conference abstracts, and www.google.my for genetic association studies up to ... Epilepsy (ILAE) was used for including studies for sub-analysis. ..... >2 years seizure freedom. Various. Various. C/C. 14. 5. Seo et al.**. 2006. Japan.
Nov 20, 2015 - Treatment Response in Polish Population â Preliminary. Report. Agnieszka ..... The mean of HDRS I and the median of the HDRS change were ...
Allele and genotype frequencies of polymorphic cytochromes P450 (DPYD) in the · Egyptian population. Br. J. Clin. Pharmacol. 450, 596â603. 318. S. Nassar et ...
Mar 1, 2012 - (ABCB1 C3435T and ABCG2 C421A) were investigated among. Malaysian CML patients undergoing IM treatment. Peripheral blood was ...
Rekha Priyadarshini* Smitha Kayal** Ramesh A*** Deepak Gopal Shewade*. *Department of Pharmacology, **Department of Medical Oncology, ***Department ...
Army Medical College, National University of Sciences & Technology (NUST) Islamabad, *Institute of Biomedical & ... representation from all regions of Pakistan.
Jun 12, 2007 - Centre, Crewe Road, Edinburgh EH4 2XR, UK. E-mail: [email protected]. Received 18 January 2007; revised 8 May. 2007; accepted ...
May 1, 2018 - Jason Hansen Karnes,. University of Arizona, United ...... Perloff, M. D., von Moltke, L. L., Störmer, E., Shader, R. I., and Greenblatt,. D., J. (2001).
Nov 27, 2012 - MBF Bioscience, National Health and Medical Research. Council, Novartis, Organon, Servier and Stanley Medical. Research Foundation; and ...
Jun 21, 2015 - Substantial portions of this article were found to have been published previously by: G. Dessilly, L. Elens, N. Panin, A. Capron,. A. Decottignies ...
drugs (anthracyclines, Daunorubicin, Vincristeine, Mitoxanthrone) which are P-gp substrates, leading to lower intra cellular drug concentrations and a poor ...
Sep 15, 2009 - hematologic toxicities after anthracycline-based chemotherapy. A significant association between allele frequencies and histological type, ...
Sep 16, 2014 - 4 CoE Research and Teaching of Molecular Biology of Matrix and Nanotechnology,. Network .... ilepsy, all of them Polish (European continental origin, Silesian .... genotype frequencies of the MDR1 polymorphism were tested.
According to Globocan 2012, breast cancer is the most common female malignancy and the second most common cancer worldwide1. This type of cancer is ...
administered digoxin (0.25 mg daily) and methyldigoxin (0.50 mg daily), some of them co-medicated with known P- ... Pharmacological Reports, 2007, 59, 107â111 ... extraction method. ... applied by our laboratory [12]. .... Gupta SK, Fromm MF: Piper
Marco Crimi*,1, Roberto Del Bo1, Sara Galbiati1, Monica Sciacco1, Andreina ... 1Centro Dino Ferrari, Centro di eccellenza per le malattie neuro-degenerative, ...
Aug 29, 2012 - When compared with homozygous GG genotype carriers, A allele carriers showed higher delta spectral power in Stage 1 and Stages 3+4 of ...
Dec 26, 2011 - Rauch A, Kutalik Z, Descombes p, Cai T, Di Iulio J, Mueller T, et al. Genetic ... De nicola S, Aghemo A, Rumi MG, Galmozzi e, Valenti L, Soffredi-.
ODT and NDT are further converted to lowly active N,. O-didesmethylate (NODT) by their CYPs. The aim of this study was to evaluate the influence of CYP2D6 ...
Clinical Therapeutics ABCB1 C3435T Polymorphism Affects In Different Ways The Pharmacokinetics of Antipsychotics and Antidepressants M. Saiz-Rodríguez; C. Belmonte; T. Cabaleiro; R. López-Rodríguez; M. Román; D. Ochoa; M. Talegón; and F Abad-Santos Hospital Universitario de la Princesa, Madrid, Spain Background: P-glycoprotein, encoded by ABCB1 gene, is an ATPdependent drug efflux pump which exports substances outside the cell. The T allele of C3435T polymorphism is frequently associated with a slower metabolizer phenotype, so homozygous T/T individuals could show higher plasma levels. The aim of the present study was to evaluate the effect of this polymorphism on pharmacokinetics (PK) of 4 antipsychotics (olanzapine, quetiapine, risperidone and aripiprazol) and 3 antidepressants (trazodone, sertraline and citalopram). Methods: 445 healthy volunteers receiving a single oral dose were genotyped by real time PCR. Plasma concentrations were measured by HPLC/ MS/MS. PK parameters were calculated using non-compartmental analysis and were compared by ANOVA or T-test. Study was approved by local research ethics committee and all subjects signed an informed consent. Results: As shown in the following table, C3435T polymorphism had no significant effect on olanzapine, quetiapine, sertraline or citalopram. As expected, T allele carriers showed a higher AUC and T1/2 for aripiprazol. Surprisingly, clearance of risperidone was higher in T carriers and clearance of trazodone was higher in T/T. ABCB1 genotype C/T+T/T
